Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Payables (2023 - 2025)

Monte Rosa Therapeutics' Payables history spans 3 years, with the latest figure at $26.7 million for Q4 2025.

  • For Q4 2025, Payables rose 42.1% year-over-year to $26.7 million; the TTM value through Dec 2025 reached $26.7 million, up 42.1%, while the annual FY2025 figure was $26.7 million, 42.1% up from the prior year.
  • Payables reached $26.7 million in Q4 2025 per GLUE's latest filing, up from $14.5 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $26.7 million in Q4 2025 to a low of $4.0 million in Q3 2024.
  • Average Payables over 3 years is $12.0 million, with a median of $12.0 million recorded in 2023.
  • Peak YoY movement for Payables: tumbled 72.04% in 2024, then soared 264.73% in 2025.
  • A 3-year view of Payables shows it stood at $11.2 million in 2023, then skyrocketed by 68.45% to $18.8 million in 2024, then surged by 42.1% to $26.7 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Payables are $26.7 million (Q4 2025), $14.5 million (Q3 2025), and $5.6 million (Q2 2025).